Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44 1250400002

About The Journal Open Access

Journal of Cancer Immunology & Therapy

The journal welcomes submissions from all related fields to the Cancer Immunology & Therapy which utilises the immune system as a treatment for cancer. Cancer immunology is an interdisciplinary branch of biology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well-known application is cancer immunotherapy.

Aims and Scope

Journal of Cancer Immunology & Therapy is a peer-reviewed, open access journal that reflects articles on all types of tumor immunology. The journal serves as a forum for new concepts and advances in basic Cancer Discovery, Cancer Epidemiology, Biomarkers & Prevention, Cancer Immunology Research, Cancer Surgery, Advances in Cancer Prevention, Breast Cancer, Cancer Biology, Cancer Treatment, Cancer Management and Research, Integrative Cancer Therapies, Clinical cancer immunology and therapy.

Journal of Cancer Immunology & Therapy organize a new platform for the researchers, scientists, scholars, students in this field to publish their research work & update the latest research information to the scientific community. Chief criteria for acceptance are scientific novelty and quality, originality, clarity, and conciseness with early online publication, regular podcasts and an immense archive collection.

You can submit your manuscript at https://www.scholarscentral.org/submissions/cancer-immunology-therapy.html as an email attachment to the e-mail id [email protected]

Please submit your manuscript to
[email protected]

Just Published Articles View More

Commentary September 06, 2021

P.1-1

J Cancer Immunol Ther: 4(4): 1-1

The Hazard of Survival Depends on the Sort of Cancer and Extent of Ailment at the Start of Remedy

John Tidy

Commentary September 06, 2021

P.1-1

J Cancer Immunol Ther: 4(4): 1-1

Most Women Diagnosed with Stage Iii Ovarian Cancer have a Five-Year Survival Rate of Approximately 39%

Donaldson Brett

Perspective September 06, 2021

P.1-1

J Cancer Immunol Ther: 4(4): 1-1

Aromatase inhibitors (ais) are a class of medication used within the remedy of breast cancer.

Sarah Luca

Editorial September 06, 2021

P.1-1

J Cancer Immunol Ther: 4(4): 1-1

Inside the extra conventional method to prostatectomy.

David James

Editorial September 06, 2021

P.1-1

J Cancer Immunol Ther: 4(4): 1-1

Palliative surgery can be carried out if tests show that the most cancers is simply too massive.

Iñaki Arrotegui

Commentary September 02, 2021

P.1-2

J Cancer Immunol Ther: 4(3): 1-2

Immunotherapy for Cancer

Ahmed Khadil*

Relevant Topics

Get the App